← Back to all trials
Terminated
NCT05701800
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
Conditions: Herpes Zoster
Sex: All
Ages: 50 Years – N/A
Healthy volunteers: Yes
Phase: PHASE1
Enrollment: 659
Sponsor: ModernaTX, Inc.
Location: Velocity Clinical Research - Westlake Los Angeles California
Summary
The purpose of this first-in-human study is to evaluate the safety and immunogenicity of mRNA-1468.
Eligibility Criteria
Inclusion Criteria:
* Part 1: Is an adult 50 years of age or older at the time of consent. Part 2: Is an adult 50-69 years of age at the time of consent.
* Has a body mass index of 18 to \14 days in total within 180 days prior to Screening Visit (for corticosteroids ≥10 milligrams/day of prednisone or equivalent) or is anticipating the need for systemic immunosuppressive treatment at any time during participation in the study. Inhaled, nasal, intra-articular and topical steroids are allowed.
* Has received systemic immunoglobulins, long-acting biological therapies that affect immune responses (for example, Infliximab) or blood products within 90 days prior to the Screening Visit or plans to receive them during the study.
Other protocol-defined inclusion/exclusion criteria apply.
Source: ClinicalTrials.gov (NCT05701800). StuddyBuddy aggregates publicly available trial information.
